# Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and Obesity

> **NCT03051451** · PHASE2 · SUSPENDED · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 150 (estimated)

## Conditions studied

- Overweight and Obesity

## Interventions

- **DRUG:** combination metformin hydrochloride/ fluoxetine 500/20 mg
- **DRUG:** combination metformin hydrochloride/ fluoxetine 1000/20mg
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03051451
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** —
- **Primary completion:** 2018-05
- **Final completion:** 2018-11
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Business decision
- **Last updated:** 2017-09-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03051451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03051451, "Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and Obesity". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03051451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*